Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
formulation switching
Description:
The change from one version or dosage form of a medicine to another, such as switching between formulations of the same drug.
Related topics:
Thyroid Disorders and Treatments (9%),
Schizophrenia research and treatment (9%),
Renal Transplantation Outcomes and Treatments (7%)
OpenAlex ID:
keywords/formulation-switching
Pharmacokinetics and Tolerability of a Microemulsion Formulation of Cyclosporine in Renal Allograft Recipients—a Concentration-controlled Comparison With the Commercial Formulation
1994
·
Edgar A. Mueller
, John M. Kovarik
, et al.
·
Transplantation
·
149
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
2013
·
David Coghill
, Tobias Banaschewski
, et al.
·
BMC Psychiatry
·
141
PDF
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
2015
·
Gerd R Burmester
, Andrea Rubbert-Roth
, et al.
·
Annals of the Rheumatic Diseases
·
132
PDF
Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study
2008
·
Fabrizio Stocchi
, Bonnie P. Hersh
, et al.
·
Current Medical Research and Opinion
·
109
Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity
2014
·
Dong Sik Jung
, Frank P. Tverdek
, et al.
·
Antimicrobial Agents and Chemotherapy
·
98
Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population‐based study
2008
·
L. A. Donnelly
, A. D. Morris
, et al.
·
Diabetes Obesity and Metabolism
·
86
Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis
2018
·
Camilla Virili
, Luca Giovanella
, et al.
·
Frontiers in Endocrinology
·
65
PDF
Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value
2009
·
Emilio Perucca
·
Epiliepsy currents/Epilepsy currents
·
55
Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution
2019
·
Salvatore Benvenga
, Allan Carlé
·
Advances in Therapy
·
52
PDF
A multicenter, open-label, sequential study comparingpreferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease
2005
·
Paul A. Nausieda
, Ronald F. Pfeiffer
, et al.
·
Clinical Therapeutics
·
51
Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy
2020
·
Uwe Walter
, Christopher Mühlenhoff
, et al.
·
Neurology
·
49
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients
2008
·
H. R. Henney
, J. D. Runyan
·
International Journal of Clinical Practice
·
46
Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients
2005
·
Victor William Armstrong
, Gero Tenderich
, et al.
·
Therapeutic Drug Monitoring
·
46
Dose Conversion Between Tapentadol Immediate and Extended Release for Low Back Pain
2010
·
Mila S. Etropolski
, Akiko Okamoto
, et al.
·
Pain Physician
·
45
Generic clozapine: outcomes after switching formulations
2006
·
Carol Paton
·
The British Journal of Psychiatry
·
45
PDF
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
2004
·
Lieuwe de Haan
, Therese van Amelsvoort
, et al.
·
Psychopharmacology
·
45
Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial
2012
·
Yoshikuni Mizuno
, Mitsutoshi Yamamoto
, et al.
·
Clinical Neuropharmacology
·
42
Clinical Problems with Generic Antiepileptic Drugs: Comparison of Sustained-Release Formulations of Carbamazepine
1999
·
Thomas Mayer
, TW May
, et al.
·
Clinical Drug Investigation
·
39
Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH: Results of a 3-week open-label study
2005
·
H. Remschmidt
, P. Hoare
, et al.
·
European Child & Adolescent Psychiatry
·
37
Oral 5-ASA Therapy in Ulcerative Colitis: What are the Implications of the New Formulations?
2008
·
William J. Sandborn
·
Journal of Clinical Gastroenterology
·
36
Switching Between Cyclosporin Formulations What are the Risks?
1997
·
Ali J. Olyaei
, Angelo M. deMattos
, et al.
·
Drug Safety
·
35
Bioequivalence of Clozapine Orally Disintegrating 100-mg Tablets Compared with Clozapine Solid Oral 100-mg Tablets after Multiple Doses in Patients with Schizophrenia
2008
·
Gil Golden
, Gilbert Honigfeld
·
Clinical Drug Investigation
·
33
Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial
2004
·
Michael Privitera
, David M. Ficker
·
Epilepsy & Behavior
·
33
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
2015
·
Srihari Gopal
, An Vermeulen
, et al.
·
Current Medical Research and Opinion
·
32
Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis
2009
·
Dana Andersen
·
Therapeutics and Clinical Risk Management
·
32
PDF
Show more works
View as search
Works count:
191
Citation count:
2,281
Year
Topic
Type